Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease

  • Authors:
    • Rakesh Singal
    • Larry Ferdinand
    • Isildinha M. Reis
    • James J. Schlesselman
  • View Affiliations

  • Published online on: September 1, 2004     https://doi.org/10.3892/or.12.3.631
  • Pages: 631-637
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Promoter methylation plays an important role in the inactivation of tumor suppressor genes during tumorigenesis. We examined the methylation status of glutathione s-transferase Pi1 (GSTP1), retinoic acid receptor beta (RARB), CD44, E-cadherin (ECAD), RAS association domain family protein 1A (RASSF1A) and endothelin B receptor (EDNRB) genes in 81 prostate cancer and 42 benign prostatic hyperpasia specimens. Genomic DNA was isolated from archived formaldehyde-fixed and paraffin-embedded tissue blocks. Methylation-specific PCR (MSP) was carried out after bisulfite treatment of genomic DNA. Methylation frequencies in prostate cancer and benign prostatic hyperplasia were 72% and 5% for GSTP1, 40% and 0% for RARB, 72% and 38% for CD44, 61% and 14% for ECAD, 49% and 19% for RASSF1A and 72% and 62% for EDNRB, respectively. Methylation of GSTP1, RARB, CD44, ECAD and RASSF1A, but not of EDNRB was detected at a statistically higher frequency in prostate cancer than in the benign prostatic hypertrophy specimens. Methylation of RARB occurred more frequently in early onset (age <55 years) as compared to late onset disease (age >70 years) (odds ratio, 8.6; 95% CI, 1.4-51.4; P=0.02). Methylation of RARB also occurred more frequently in stage III as compared to stage II disease (odds ratio, 3.2; 95% CI, 1.1-8.8; P=0.03). A methylation index (MI) was calculated as the total number of genes methylated, excluding EDNRB. A trend toward higher MI was noted in stage III as compared to stage II disease, and in Gleason score 7 as compared to Gleason score 6 tumors. Our results suggest that the methylation of selected genes in prostate cancers correlates with clinicopathological features of poor prognosis.

Related Articles

Journal Cover

September 2004
Volume 12 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Singal R, Ferdinand L, Reis IM and Schlesselman JJ: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 12: 631-637, 2004.
APA
Singal, R., Ferdinand, L., Reis, I.M., & Schlesselman, J.J. (2004). Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncology Reports, 12, 631-637. https://doi.org/10.3892/or.12.3.631
MLA
Singal, R., Ferdinand, L., Reis, I. M., Schlesselman, J. J."Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease". Oncology Reports 12.3 (2004): 631-637.
Chicago
Singal, R., Ferdinand, L., Reis, I. M., Schlesselman, J. J."Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease". Oncology Reports 12, no. 3 (2004): 631-637. https://doi.org/10.3892/or.12.3.631